Menlo Therapeutics Inc. (MNLO)
Stock Price:
$1.60 USD
-0.03 (-1.54%)
Updated Jul 16, 2020 10:59 AM EDT - Market open
Key Info
| Market Cap |
267.36M |
| Revenue (ttm) |
1.89M |
| Net Income (ttm) |
-95.06M |
| Shares Out |
167.62M |
| EPS (ttm) |
-2.01 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 16, 2020 |
| Last Price |
$1.60 |
| Previous Close |
$1.62 |
| Change ($) |
-0.03 |
| Change (%) |
-1.54% |
| Day's Open |
1.61 |
| Day's Range |
1.55 - 1.62 |
| Day's Volume |
663,108 |
| 52-Week Range |
1.00 - 7.48 |
More Stats
| Market Cap |
267.36M |
| Enterprise Value |
219.24M |
| Earnings Date (est) |
Jul 30, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
167.62M |
| Float |
114.90M |
| EPS (basic) |
-3.23 |
| EPS (diluted) |
-2.01 |
| FCF / Share |
-2.34 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
11.24M |
| Short Ratio |
1.62 |
| Short % of Float |
7.87% |
| Beta |
1.69 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
141.83 |
| PB Ratio |
3.78 |
| Revenue |
1.89M |
| Operating Income |
-96.46M |
| Net Income |
-95.06M |
| Free Cash Flow |
-99.29M |
| Net Cash |
48.11M |
| Net Cash / Share |
0.29 |
| Gross Margin |
23.50% |
| Operating Margin |
-5,117.29% |
| Profit Margin |
-5,432.20% |
| FCF Margin |
-5,267.37% |
| ROA |
-54.07% |
| ROE |
-162.96% |
| ROIC |
-182.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
8 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$6.56*
(311.29% upside)
Low
2.50
Current: 1.60
High
15.00
Target: 6.56
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | 10.64 | 4.58 | 0.67 | - |
| Revenue Growth | - | 132.21% | 579.82% | - | - |
| Gross Profit | - | 10.64 | 4.58 | 0.67 | - |
| Operating Income | -76.24 | -54.54 | -29.59 | -14.33 | -4.61 |
| Net Income | -73.70 | -51.45 | -29.08 | -14.07 | -4.61 |
| Shares Outstanding | 23.82 | 21.67 | 5.11 | 4.99 | 4.74 |
| Earnings Per Share | -3.09 | -2.37 | -5.69 | -2.82 | -0.97 |
| Operating Cash Flow | -65.10 | -52.73 | -28.22 | -2.27 | -4.18 |
| Capital Expenditures | -0.01 | -0.14 | -0.03 | -0.03 | - |
| Free Cash Flow | -65.11 | -52.87 | -28.25 | -2.30 | -4.18 |
| Cash & Equivalents | 73.37 | 136 | 59.50 | 30.91 | 43.81 |
| Total Debt | 34.47 | - | - | - | - |
| Net Cash / Debt | 38.90 | 136 | 59.50 | 30.91 | 43.81 |
| Assets | 81.16 | 140 | 66.87 | 42.05 | 43.89 |
| Liabilities | 63.58 | 9.55 | 14.57 | 12.49 | 0.84 |
| Book Value | 17.58 | 130 | -57.03 | -29.44 | -15.95 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Menlo Therapeutics Inc. |
| Country |
United States |
| Employees |
180 |
| CEO |
David Domzalski |
Stock Information
| Ticker Symbol |
MNLO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MNLO |
| IPO Date |
January 25, 2018 |
Description
Menlo Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris. In addition, it is developing Serlopitant, a once-daily oral NK1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. The company was founded in 2003 and is headquartered in Bridgewater, New Jersey.